Nasopharyngeal Carcinoma (Enhanced Edition) Nasopharyngeal Carcinoma (Enhanced Edition)

Nasopharyngeal Carcinoma (Enhanced Edition‪)‬

From Etiology to Clinical Practice

Anne Wm Lee and Others
    • $179.99
    • $179.99

Publisher Description

Nasopharyngeal Carcinoma: From Etiology to Clinical Practice discusses NPC from basic science, to clinical management through the perspective of members of the Centre for Nasopharyngeal Carcinoma Research in Hong Kong. It encompasses not only the most detailed information about multiple aspects of NPC, but also the modern day research model of scientist-clinician collaboration, focusing on bench-to-bedside approach. Basic science is covered, discussing genetics and genomics in NPC and its epidemiology and the role of Epstein-Barr Virus (EBV). Translational research is also covered, presenting topics such as animal models, plasma EBV DNA, molecular imaging and immunotherapy, amongst other topics.

This book is a valuable source for cancer researchers, oncologists, medical oncologists and several members of the biomedical field who are interested in learning more about NPC management from both clinical and research perspectives. Written by members of the Centre for Nasopharyngeal Carcinoma Research Extensively covers various aspects of NPC, including basic science and the clinical advances of both scientists and clinicians Discusses the molecular information gained through laboratory studies to stimulate research on new treatment strategies

GENRE
Professional & Technical
RELEASED
2019
March 23
LANGUAGE
EN
English
LENGTH
394
Pages
PUBLISHER
Elsevier Science
SELLER
Elsevier Ltd.
SIZE
89.2
MB

More Books Like This

Phenotyping of N-Acetyltransferase 2 in Male Volunteers by Hplc (Report) Phenotyping of N-Acetyltransferase 2 in Male Volunteers by Hplc (Report)
2011
Decision Analytics and Optimization in Disease Prevention and Treatment Decision Analytics and Optimization in Disease Prevention and Treatment
2018
Glaxosmithkline Announces Swiss Approval of Duodart(R); The First Fixed Dose Combination Medicine for Benign Prostatic Hyperplasia Glaxosmithkline Announces Swiss Approval of Duodart(R); The First Fixed Dose Combination Medicine for Benign Prostatic Hyperplasia
2010
Environmental Technology and Engineering Techniques Environmental Technology and Engineering Techniques
2020
Comprehensive Bioactive Natural Products (Efficacy, Safety & Clinical Evaluation II) Comprehensive Bioactive Natural Products (Efficacy, Safety & Clinical Evaluation II)
2010
Recent Progress In Medicinal Plants (Phytotherapeutics II) Recent Progress In Medicinal Plants (Phytotherapeutics II)
2016